• Loading stock data…

ProMIS Neurosciences Doses First Subjects in Phase 1a Clinical Trial of PMN310 to Treat Alzheimer’s Disease

Last Updated on November 20, 2023 by


Print Friendly, PDF & Email
Spread the word

Reader Interactions

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Generated by Feedzy